JP2024546106A5 - - Google Patents
Info
- Publication number
- JP2024546106A5 JP2024546106A5 JP2024534244A JP2024534244A JP2024546106A5 JP 2024546106 A5 JP2024546106 A5 JP 2024546106A5 JP 2024534244 A JP2024534244 A JP 2024534244A JP 2024534244 A JP2024534244 A JP 2024534244A JP 2024546106 A5 JP2024546106 A5 JP 2024546106A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286896P | 2021-12-07 | 2021-12-07 | |
| US63/286,896 | 2021-12-07 | ||
| PCT/US2022/052135 WO2023107560A1 (en) | 2021-12-07 | 2022-12-07 | Dlk1 antibodies and methods of treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546106A JP2024546106A (ja) | 2024-12-17 |
| JP2024546106A5 true JP2024546106A5 (https=) | 2026-01-14 |
| JPWO2023107560A5 JPWO2023107560A5 (https=) | 2026-01-14 |
Family
ID=86731155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534244A Pending JP2024546106A (ja) | 2021-12-07 | 2022-12-07 | Ｄｌｋ１抗体及びがんを処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250042992A1 (https=) |
| EP (1) | EP4444350A4 (https=) |
| JP (1) | JP2024546106A (https=) |
| KR (1) | KR20240130094A (https=) |
| CN (1) | CN119486755A (https=) |
| AU (1) | AU2022408069A1 (https=) |
| CA (1) | CA3240297A1 (https=) |
| IL (1) | IL313298A (https=) |
| MX (1) | MX2024006969A (https=) |
| WO (1) | WO2023107560A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120737193B (zh) * | 2025-09-03 | 2025-12-16 | 中山大学 | 一种抗Oya病毒核衣壳蛋白的单克隆抗体或其抗原结合片段及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073641B (zh) * | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
| ES2527521T3 (es) * | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
| DK2421898T3 (en) * | 2009-04-20 | 2016-05-30 | Oxford Biotherapeutics Ltd | Cadherin-17 SPECIFIC ANTIBODIES |
| US10226535B2 (en) * | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| KR102847350B1 (ko) * | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법 |
| KR102503143B1 (ko) * | 2019-03-06 | 2023-02-24 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
-
2022
- 2022-12-07 EP EP22905079.4A patent/EP4444350A4/en active Pending
- 2022-12-07 CA CA3240297A patent/CA3240297A1/en active Pending
- 2022-12-07 IL IL313298A patent/IL313298A/en unknown
- 2022-12-07 WO PCT/US2022/052135 patent/WO2023107560A1/en not_active Ceased
- 2022-12-07 KR KR1020247022228A patent/KR20240130094A/ko active Pending
- 2022-12-07 CN CN202280091022.6A patent/CN119486755A/zh active Pending
- 2022-12-07 US US18/717,891 patent/US20250042992A1/en active Pending
- 2022-12-07 JP JP2024534244A patent/JP2024546106A/ja active Pending
- 2022-12-07 MX MX2024006969A patent/MX2024006969A/es unknown
- 2022-12-07 AU AU2022408069A patent/AU2022408069A1/en active Pending